A Look Back at 2025: Progress Towards the Treatment of Aging as a Medical Condition
As 2025 winds to a close, it is time once again to look back at some of the aging and longevity research published in the past year. Matters do move forward, even in tough times. The research community continues to turn out interesting new papers, the XPRIZE Healthspan competition reached 100 participating teams, and the […]
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities
Metabolic dysfunction-associated steatohepatitis (MASH) is a multifactorial metabolic liver disease that occurs in the context of obesity, insulin resistance and cardiometabolic comorbidities. Monotherapy targeting single pathways often provides only partial improvements in histological liver fibrosis and systemic metabolic parameters, prompting growing interest in multitargeted combination therapies. Multitargeted and combination strategies for MASH can modulate multiple […]
ADHD Drugs Work Differently? Infant Screen Time; GLP-1 Psychological Side Effects
(MedPage Today) — An imaging study suggested prescription attention deficit hyperactivity disorder (ADHD) drugs may work differently than previously thought by affecting arousal and reward, not attention networks. (Cell) Post-natal depression…
New CMS Demo Aims to Increase Access to GLP-1s Under Medicaid and Part D
(MedPage Today) — The Trump administration announced a new demonstration program aimed at easing access to GLP-1 receptor agonists for enrollees in Medicare Part D and Medicaid plans, but experts say it’s unclear how popular or effective it will…
Chipotle Launches 4-Ounce Bowl of Meat for the Ozempic Age
The move signals that we’re about to see a lot more GLP-1-centric menus.
Where Will Pfizer Be in 5 Years?
Key Points Pfizer’s stock soared during the coronavirus pandemic because of its COVID-19 vaccine. The world has learned to live with the coronavirus, and Pfizer’s stock has plunged as a result. Faced with patent expirations, Pfizer is making needed investments to rebuild its growth platform. 10 stocks we like better than Pfizer › Pfizer (NYSE: […]
Ozempic is changing more than weight: New global research shows how GLP-1 drugs are reshaping self and society, identity and mental health, not just bodies. Much of the demand is driven by weight anxiety, even among medically “healthy” users. Many users endure severe side effects and high costs.
submitted by /u/mvea [link] [comments]
“Americans always want the f*cking pill,” Dr. Robert Lustig, a metabolic scientist at the University of California-San Francisco said, on why GLP-1 drugs are a Band-Aid and not a solution [Amusing]
[link] [13 comments]
Oprah Winfrey opens up on why her GLP-1 weight loss medication became lifelong choice: ‘If I stop the weight comes back’
Oprah Winfrey opens up about her weight loss journey, GLP-1 medication, and the lessons she learned about obesity, self-blame, and lifelong health management.
2 ideas for a SIPP or ISA in 2026
With markets up significantly, 2025 has likely been a great year for most SIPP and Stocks and Shares ISA investors. But what about next year? Here are two shares that I think deserve closer attention. FTSE 100 stock After a massive multiyear rally, the BAE Systems (LSE:BA.) share price peaked above 2,000p in early October. […]